

The value of anticancer drugs – a regulatory view

Nature Reviews Clinical Oncology

19, 207-215

DOI: [10.1038/s41571-021-00584-z](https://doi.org/10.1038/s41571-021-00584-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada. <i>Current Oncology</i> , 2022, 29, 2064-2072.	2.2	7
2	May phytophenolics alleviate aflatoxins-induced health challenges? A holistic insight on current landscape and future prospects. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	9
3	Role of innovation in pharmaceutical regulation: A proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspective. <i>Drug Discovery Today</i> , 2023, 28, 103526.	6.4	1
4	From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. <i>Lancet Oncology</i> , The, 2023, 24, e150-e160.	10.7	6
5	Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. <i>European Journal of Cancer</i> , 2023, 186, 52-61.	2.8	20
6	Beliefs and perspectives on the future of oncology pharmacy—collated results of member surveys of the European Society of Oncology Pharmacy. <i>European Journal of Oncology Pharmacy</i> , 2023, 6, e00043.	0.9	0
7	High-Precision Synthesis of RNA-Loaded Lipid Nanoparticles for Biomedical Applications. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	11
8	Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. <i>ESMO Open</i> , 2023, 8, 101209.	4.5	1
9	UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies. <i>Lancet Oncology</i> , The, 2023, 24, 963-966.	10.7	0
10	Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting. <i>JCO Global Oncology</i> , 2023, , .	1.8	0
11	Design, synthesis, chemical and biological evaluation of 2,5,5-trisubstituted-1,2-thiazepan-6-one 1,1-dioxides. <i>Results in Chemistry</i> , 2024, 7, 101252.	2.0	0
12	Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting. <i>European Journal of Cancer</i> , 2024, 197, 113496.	2.8	0
13	Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	1.0	0
14	The impact of level of documentation on the accessibility and affordability of new drugs in Norway. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0